A positive correlation between HER2 and CTGF expression was recently found in gallbladder cancer and matched adjacent normal tissue18. There is also evidence in breast cancer that CTGF has an association with resistance to Lapatinib, a HER2-targeting therapeutic19. This evidence concerns the gene ERBB2 and breast carcinoma.